Global Ischemia Reperfusion Injury Treatment Market Research Report 2023

Publication ID:

PB504236029

Publication Date:

May 16, 2023

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

IT Services [2]

Computing & Electronics [3]

Description:

The global Ischemia Reperfusion Injury Treatment market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Ischemia Reperfusion Injury Treatment is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Ischemia Reperfusion Injury Treatment is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Ischemia Reperfusion Injury Treatment in Hospitals is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Ischemia Reperfusion Injury Treatment include Amyndas Pharmaceuticals LLC, Angion, Bolder Biotechnology, Opsona Therapeutics Ltd., Pharming Group NV, Prolong Pharmaceuticals, Prothix BV, Stealth BioTherapeutics, Inc. and Zealand Pharma A/S, etc. In 2022, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Ischemia Reperfusion Injury Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Ischemia Reperfusion Injury Treatment.
The Ischemia Reperfusion Injury Treatment market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Ischemia Reperfusion Injury Treatment market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Ischemia Reperfusion Injury Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Amyndas Pharmaceuticals LLC
Angion
Bolder Biotechnology
Opsona Therapeutics Ltd.
Pharming Group NV
Prolong Pharmaceuticals
Prothix BV
Stealth BioTherapeutics, Inc.
Zealand Pharma A/S
Faraday Pharmaceuticals
SBI Pharmaceuticals
Segment by Type
Heart Injury
Kidney Injury
Intestine Injury
Other
Segment By Application
Hospitals
Specialty Clinics
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Ischemia Reperfusion Injury Treatment companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Ischemia Reperfusion Injury Treatment Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Heart Injury
1.2.3 Kidney Injury
1.2.4 Intestine Injury
1.2.5 Other
1.3 Market By Application
1.3.1 Global Ischemia Reperfusion Injury Treatment Market Growth By Application: 2018 VS 2022 VS 2029
1.3.2 Hospitals
1.3.3 Specialty Clinics
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Ischemia Reperfusion Injury Treatment Market Perspective (2018-2029)
2.2 Ischemia Reperfusion Injury Treatment Growth Trends by Region
2.2.1 Global Ischemia Reperfusion Injury Treatment Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Ischemia Reperfusion Injury Treatment Historic Market Size by Region (2018-2023)
2.2.3 Ischemia Reperfusion Injury Treatment Forecasted Market Size by Region (2024-2029)
2.3 Ischemia Reperfusion Injury Treatment Market Dynamics
2.3.1 Ischemia Reperfusion Injury Treatment Industry Trends
2.3.2 Ischemia Reperfusion Injury Treatment Market Drivers
2.3.3 Ischemia Reperfusion Injury Treatment Market Challenges
2.3.4 Ischemia Reperfusion Injury Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Ischemia Reperfusion Injury Treatment Players by Revenue
3.1.1 Global Top Ischemia Reperfusion Injury Treatment Players by Revenue (2018-2023)
3.1.2 Global Ischemia Reperfusion Injury Treatment Revenue Market Share by Players (2018-2023)
3.2 Global Ischemia Reperfusion Injury Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Ischemia Reperfusion Injury Treatment Revenue
3.4 Global Ischemia Reperfusion Injury Treatment Market Concentration Ratio
3.4.1 Global Ischemia Reperfusion Injury Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Ischemia Reperfusion Injury Treatment Revenue in 2022
3.5 Ischemia Reperfusion Injury Treatment Key Players Head office and Area Served
3.6 Key Players Ischemia Reperfusion Injury Treatment Product Solution and Service
3.7 Date of Enter into Ischemia Reperfusion Injury Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Ischemia Reperfusion Injury Treatment Breakdown Data by Type
4.1 Global Ischemia Reperfusion Injury Treatment Historic Market Size by Type (2018-2023)
4.2 Global Ischemia Reperfusion Injury Treatment Forecasted Market Size by Type (2024-2029)
5 Ischemia Reperfusion Injury Treatment Breakdown Data By Application
5.1 Global Ischemia Reperfusion Injury Treatment Historic Market Size By Application (2018-2023)
5.2 Global Ischemia Reperfusion Injury Treatment Forecasted Market Size By Application (2024-2029)
6 North America
6.1 North America Ischemia Reperfusion Injury Treatment Market Size (2018-2029)
6.2 North America Ischemia Reperfusion Injury Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Ischemia Reperfusion Injury Treatment Market Size by Country (2018-2023)
6.4 North America Ischemia Reperfusion Injury Treatment Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Ischemia Reperfusion Injury Treatment Market Size (2018-2029)
7.2 Europe Ischemia Reperfusion Injury Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Ischemia Reperfusion Injury Treatment Market Size by Country (2018-2023)
7.4 Europe Ischemia Reperfusion Injury Treatment Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Ischemia Reperfusion Injury Treatment Market Size (2018-2029)
8.2 Asia-Pacific Ischemia Reperfusion Injury Treatment Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Ischemia Reperfusion Injury Treatment Market Size by Region (2018-2023)
8.4 Asia-Pacific Ischemia Reperfusion Injury Treatment Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Ischemia Reperfusion Injury Treatment Market Size (2018-2029)
9.2 Latin America Ischemia Reperfusion Injury Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Ischemia Reperfusion Injury Treatment Market Size by Country (2018-2023)
9.4 Latin America Ischemia Reperfusion Injury Treatment Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Ischemia Reperfusion Injury Treatment Market Size (2018-2029)
10.2 Middle East & Africa Ischemia Reperfusion Injury Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Ischemia Reperfusion Injury Treatment Market Size by Country (2018-2023)
10.4 Middle East & Africa Ischemia Reperfusion Injury Treatment Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Amyndas Pharmaceuticals LLC
11.1.1 Amyndas Pharmaceuticals LLC Company Detail
11.1.2 Amyndas Pharmaceuticals LLC Business Overview
11.1.3 Amyndas Pharmaceuticals LLC Ischemia Reperfusion Injury Treatment Introduction
11.1.4 Amyndas Pharmaceuticals LLC Revenue in Ischemia Reperfusion Injury Treatment Business (2018-2023)
11.1.5 Amyndas Pharmaceuticals LLC Recent Development
11.2 Angion
11.2.1 Angion Company Detail
11.2.2 Angion Business Overview
11.2.3 Angion Ischemia Reperfusion Injury Treatment Introduction
11.2.4 Angion Revenue in Ischemia Reperfusion Injury Treatment Business (2018-2023)
11.2.5 Angion Recent Development
11.3 Bolder Biotechnology
11.3.1 Bolder Biotechnology Company Detail
11.3.2 Bolder Biotechnology Business Overview
11.3.3 Bolder Biotechnology Ischemia Reperfusion Injury Treatment Introduction
11.3.4 Bolder Biotechnology Revenue in Ischemia Reperfusion Injury Treatment Business (2018-2023)
11.3.5 Bolder Biotechnology Recent Development
11.4 Opsona Therapeutics Ltd.
11.4.1 Opsona Therapeutics Ltd. Company Detail
11.4.2 Opsona Therapeutics Ltd. Business Overview
11.4.3 Opsona Therapeutics Ltd. Ischemia Reperfusion Injury Treatment Introduction
11.4.4 Opsona Therapeutics Ltd. Revenue in Ischemia Reperfusion Injury Treatment Business (2018-2023)
11.4.5 Opsona Therapeutics Ltd. Recent Development
11.5 Pharming Group NV
11.5.1 Pharming Group NV Company Detail
11.5.2 Pharming Group NV Business Overview
11.5.3 Pharming Group NV Ischemia Reperfusion Injury Treatment Introduction
11.5.4 Pharming Group NV Revenue in Ischemia Reperfusion Injury Treatment Business (2018-2023)
11.5.5 Pharming Group NV Recent Development
11.6 Prolong Pharmaceuticals
11.6.1 Prolong Pharmaceuticals Company Detail
11.6.2 Prolong Pharmaceuticals Business Overview
11.6.3 Prolong Pharmaceuticals Ischemia Reperfusion Injury Treatment Introduction
11.6.4 Prolong Pharmaceuticals Revenue in Ischemia Reperfusion Injury Treatment Business (2018-2023)
11.6.5 Prolong Pharmaceuticals Recent Development
11.7 Prothix BV
11.7.1 Prothix BV Company Detail
11.7.2 Prothix BV Business Overview
11.7.3 Prothix BV Ischemia Reperfusion Injury Treatment Introduction
11.7.4 Prothix BV Revenue in Ischemia Reperfusion Injury Treatment Business (2018-2023)
11.7.5 Prothix BV Recent Development
11.8 Stealth BioTherapeutics, Inc.
11.8.1 Stealth BioTherapeutics, Inc. Company Detail
11.8.2 Stealth BioTherapeutics, Inc. Business Overview
11.8.3 Stealth BioTherapeutics, Inc. Ischemia Reperfusion Injury Treatment Introduction
11.8.4 Stealth BioTherapeutics, Inc. Revenue in Ischemia Reperfusion Injury Treatment Business (2018-2023)
11.8.5 Stealth BioTherapeutics, Inc. Recent Development
11.9 Zealand Pharma A/S
11.9.1 Zealand Pharma A/S Company Detail
11.9.2 Zealand Pharma A/S Business Overview
11.9.3 Zealand Pharma A/S Ischemia Reperfusion Injury Treatment Introduction
11.9.4 Zealand Pharma A/S Revenue in Ischemia Reperfusion Injury Treatment Business (2018-2023)
11.9.5 Zealand Pharma A/S Recent Development
11.10 Faraday Pharmaceuticals
11.10.1 Faraday Pharmaceuticals Company Detail
11.10.2 Faraday Pharmaceuticals Business Overview
11.10.3 Faraday Pharmaceuticals Ischemia Reperfusion Injury Treatment Introduction
11.10.4 Faraday Pharmaceuticals Revenue in Ischemia Reperfusion Injury Treatment Business (2018-2023)
11.10.5 Faraday Pharmaceuticals Recent Development
11.11 SBI Pharmaceuticals
11.11.1 SBI Pharmaceuticals Company Detail
11.11.2 SBI Pharmaceuticals Business Overview
11.11.3 SBI Pharmaceuticals Ischemia Reperfusion Injury Treatment Introduction
11.11.4 SBI Pharmaceuticals Revenue in Ischemia Reperfusion Injury Treatment Business (2018-2023)
11.11.5 SBI Pharmaceuticals Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

Amyndas Pharmaceuticals LLC
Angion
Bolder Biotechnology
Opsona Therapeutics Ltd.
Pharming Group NV
Prolong Pharmaceuticals
Prothix BV
Stealth BioTherapeutics, Inc.
Zealand Pharma A/S
Faraday Pharmaceuticals
SBI Pharmaceuticals

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂